Rimantadine in combination with sodium alginate as a means of treatment and prevention of acute respiratory viral infections of various etiologies in infants and preschool children

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. The annual seasonal rise in the incidence of acute respiratory viral infections (ARVI) begins in September with maximum incidence rate among infants and preschool children. In November-December, influenza begins to dominate, first in the form of local outbreaks, and then an epidemic rise in incidence of varying intensity. In the fall of 2021, against the backdrop of the ongoing incidence of COVID-19, influenza viruses returned to epidemic circulation both in the world and in Russia, causing in 2022 –2023 increase in influenza activity, first caused mainly by the influenza A(H1N1)pdm09 virus, and then by influenza B.

Objective. Summarizing the results of evaluation of the therapeutic and preventive efficacy of rimantadine + sodium alginate for ARVI of various etiologies in infants and preschool children.

Methods. The therapeutic efficacy of rimantadine + sodium alginate was studied in 808 children hospitalized on days 1–2 of acute respiratory viral infection with a proven etiology of the disease. The latter was established by detecting pathogen antigens in material from the nasal passages and nasopharynx of patients using the polymerase chain reaction or immunofluorescence express method, followed (after 2–3 days and before discharge) by determining their persistence or the appearance of new pathogens, as well as serologically in paired blood sera: in complement fixation reactions, hemagglutination inhibition and enzyme immunoassay with a wide range of antigens. The preventive effectiveness of the drug was studied during 6 outbreaks of ARVI in 269 children from 3 orphanages: 134 children received the drug, 135 were included in the comparison group.

Conclusion. Clinical and epidemiological observations have shown that the polymer drug, consisted of a complex derivative of rimantadine and modified sodium alginate from seaweed in sugar syrup, has statistically significantly proven therapeutic and preventive efficacy in ARVI of any etiology in children aged 1–7 years.

Full Text

Restricted Access

About the authors

Lyudmila V. Osidak

Smorodintsev Research Institute of Influenza

Author for correspondence.
Email: Lvosidak@mail.ru
ORCID iD: 0000-0003-1140-3158

Dr. Sci. (Med.), Professor, Leading Researcher at the Department of RVI in Children

Russian Federation, St. Petersburg

O. I. Afanasyeva

Smorodintsev Research Institute of Influenza

Email: Lvosidak@mail.ru
ORCID iD: 0000-0002-1229-171X
Russian Federation, St. Petersburg

E. G. Golovacheva

Smorodintsev Research Institute of Influenza

Email: Lvosidak@mail.ru
ORCID iD: 0000-0002-1934-7288
Russian Federation, St. Petersburg

E. S. Goncharova

Smorodintsev Research Institute of Influenza

Email: Lvosidak@mail.ru
Russian Federation, St. Petersburg

E. V. Obraztsova

Smorodintsev Research Institute of Influenza

Email: Lvosidak@mail.ru
ORCID iD: 0000-0001-8762-6724
Russian Federation, St. Petersburg

E. S. Goncharova

Smorodintsev Research Institute of Influenza

Email: Lvosidak@mail.ru
ORCID iD: 0000-0002-1615-9919
Russian Federation, St. Petersburg

References

  1. Осидак Л.В., Дондурей Е.А., Образцова Е.В. и др. Структура заболеваемости и современные подходы к терапии ОРВИ у детей. РМЖ. Медицинское обозрение. 2019;3:33–8. [Osidak L.V., Dondurey E.A., Obraztsova E.V., et al. Morbidity pattern and modern approaches to ARVI treatment in children. RMJ. Med Rev. 2019;3:33–8. (In Russ.)].
  2. Осидак Л.В., Головачева Е.Г., Афанасьева О.И. и др. Лечим ОРВИ у детей раннего возраста Фарматека. 2020;27(9):36–43. [Osidak L.V., Golovacheva E.G., Afanasieva O.I., et al. Farmateka. 2020;27(9):36–43. (In Russ.)]. doi: 10.18565/pharmateca.2020.9.36-43.
  3. Weekly epidemiology record. Recommended composition of influenza virus vaccines for use in the 2022 southern hemisphere influenza season. 2021;96(42):509–20. URL: https://www.who.int/publications/m/item/influenza-update-n-435
  4. Еженедельный Национальный бюллетень по гриппу и ОРВИ, 39-я неделя 2022 г. [National weekly influenza bulletin of the Russian Federation week 39 of 2022. (In Russ.). URL: https://influenza.spb.ru/
  5. Influenza Update WHO. 2023. 435 p.
  6. Еженедельный Национальный бюллетень по гриппу и ОРВИ, 20-я неделя 2023 г. (National weekly influenza bulletin of the Russian Federation week 20 of 2023). (In Russ.). URL: https://influenza.spb.ru/
  7. Платонов В.Н, Шальнова Л.И., Ильенко В.И. и др. Поиск эффективных средств профилактики и лечения гриппа в ряду полимерных соединений аминопроизводных адамантана. Химиотерапия и химиопрофилактика гриппа и ОРЗ. Сборник научных трудов. Л., 1990. С. 24–9. [Platonov V. N., Shalnova L. I., Ilyenko V. I., et al. Search for effective means of preventing and treating flu in a number of polymer compounds amino derivatives of adamantane. Chemotherapy and chemoprophylaxis of influenza and acute respiratory infections. Collection of scientific works. L., 1990. Р. 24–9. (In Russ.)].
  8. Киселев В.И., Киселев О.И., Юрьев М.З. Препарат для лечения и профилактики вирусных заболеваний. Патент 27.07.2002 г. RU (11) 2185822 (13) C2. [Kiselev V.I., Kiselev O.I., Yuryev M.Z. A drug for the treatment and prevention of viral diseases. Patent 27.07.2002. RU (11) 2185822 (13) C2. (In Russ.)].
  9. Осидак Л.В., Зарубаев В.В., Образцова Е.В. и др. Результаты сравнительного изучения противовирусной и лечебной эффективности отечественного препарата Орвирем® (римантадин+альгинат натрия) при лечении детей раннего и дошкольного возраста с острыми респираторными вирусными инфекциями. Педиатрия. 17;96(5):111–18. [Osidak L.V., Zarubaev V.V., Obraztsova E.V., et al. Resultsof a comparative study of the antiviral andtherapeutic effectiveness of the domestic drug Orvirem® (remantadine+sodium alginate) in the treatment of children of early and preschool agewith acute respiratory viral infections. Pediatrics.2017;96(5):111–8. (In Russ.)]. doi: 10.24110/0031-403X-2017-96-5-111-118.
  10. Отчет о результатах клинического эффективности препарата Альгирем у детей с гриппом и ОРВИ. СПб., Всесоюзный НИИ гриппа, 2004. 17 c. [Report on the resultsofthe clinical study of the therapeutic effectiveness ofthe drug Algirem in children with influenza and acute respiratory viralinfection. St. Petersburg, All Union Research Institute of Influenza, 2004. 17 p. (In Russ.)].
  11. Осидак Л.В., Афанасьева О.И., Дриневский В.П. и др. Новые средства лечения и профилактики гриппа и других ОРВИ. Лечащий врач. 2004;10. [Osidak L.V., Afanasyeva O.I., Drinevsky V.P., et al. New means of treatment and prevention of influenza and other acute respiratory infections. Lechashchiy vrach. 2004;10. (In Russ.)].
  12. Эрман Е.С. Оценка клинико-эпидемиологической эффективности новых средств для профилактики гриппа и ОРИ другой этиологии у часто болеющих детей. Дисс. кандидат мед. наук. СПб., 2009. [Erman E.S. Evaluation of the clinical and epidemiological effectiveness of new means for the prevention of influenza and ARI of other etiology in frequently ill children. Diss. Cand. of Med. Sci. SPb., 2009. (In Russ.)].
  13. Ершов Ф.И. Химиотерапия вирусных инфекций. Вопросы общей вирусологии: Пособие для врачей. Под. ред. О.И. Киселев, И.Н. Жилинская. 2007;8:263–312. [Yershov F. I. Chemotherapy of viral infections. Questions of General Virology: Manual for doctors. O.I. Kiselev, I.N. Zhilinskaya, ed. 2007;8:263–312. (In Russ.)].
  14. Осидак Л.В., Мурадян А.Я., Румель Н.Б., Дриневский В.П. Коронавирусная инфекция (этиология, клинико-лабораторная характеристика, противовирусная терапия): пособие для врачей. Под ред. Л.В. Осидак. СПб., 2007. 69 с. [Osidak L.V., Muradyan A.Ya., Rumel N.B., Drinevsky V.P. Coronavirus infection (etiology, clinical and laboratory characteristics, antiviral therapy): a manual for doctors. Ed. by L.V. Osidak. SPb., 2007. 69 p. (In Russ.)].
  15. Белоусов Д.Ю., Чеберда А.Е. Фармако-эпидемиологические исследования: методология и регулирование. Качественная клиническая практика. 2017;1:34–41. [Belousov D.Yu., Cheberda A.E. Pharmacoepidemiolocal research:methodology and regulation. Kachestvennaya klinicheskaya praktika. 2017;1:34–41. (In Russ.)].
  16. Сборник методических рекомендаций по выделению вирусов, ИФ и ПЦР-диагностике гриппа, вводу данных сигнального надзора в системе online, СПб., 2011. 68 с. [Collection of methodological recommendations on the isolation of viruses, IF and PCR diagnostics of influenza, the introduction of signaling surveillance data in the system. SPb., 2011. 68 p. (In Russ.)]. URL: https://www.influenza.spb.ru/files/11_influrecs-front.jpg.
  17. Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ Statistica. М., 2002. 312 с. [Rebrova O.Yu. Statistical analysis ofmedical data. Application of Statistica package. M., 2002. 312 p. (In Russ.)].
  18. Беляков В.Д., Семененко Г.А., Шрага М.К. Введение в эпидемиологию инфекционных и неинфекционных заболеваний человека. М., 2001. 262 с. [Belyakov V.D. Semenenko G.A., Shraga M.K. Introduction to the epidemiology of infectious and non–communicable human diseases M., 2001. 262 p. (In Russ.)].

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig.1.

Download (107KB)
Indexing metadata

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies